Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes. A 30-week Randomised, Double-blind, Double-dummy, Active-controlled, Parallel-group, Multi-centre and Multi-national Trial
Phase of Trial: Phase III
Latest Information Update: 14 Apr 2018
At a glance
- Drugs Semaglutide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms SUSTAIN; SUSTAIN - CHINA MRCT
- Sponsors Novo Nordisk
- 09 Apr 2018 Planned number of patients changed from 1050 to 858.
- 14 Dec 2017 Planned End Date changed from 19 Nov 2018 to 20 May 2019.
- 30 Aug 2017 Status changed from not yet recruiting to recruiting.